Oncotarget

Research Papers:

The DDGP (cisplatin, dexamethasone, gemcitabine, and pegaspargase) regimen for treatment of extranodal natural killer (NK)/T-cell lymphoma, nasal type

Lei Zhang, Sucai Li, Sisi Jia, Feifei Nan, Zhaoming Li, Jingyu Cao, Shanshan Fan, Chao Zhang, Liping Su, Jinghua Wang, Hongwei Xue and Mingzhi Zhang _

PDF  |  HTML  |  How to cite

Oncotarget. 2016; 7:58396-58404. https://doi.org/10.18632/oncotarget.11135

Metrics: PDF 2044 views  |   HTML 2354 views  |   ?  


Abstract

Lei Zhang1, Sucai Li1, Sisi Jia1, Feifei Nan1, Zhaoming Li1, Jingyu Cao1, Shanshan Fan1, Chao Zhang1, Liping Su2, Jinghua Wang3, Hongwei Xue4, Mingzhi Zhang1

1Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Lymphoma Diagnosis and Treatment Center of Henan Province, Zhengzhou, Henan, China

2Department of Hematology, Shanxi Cancer Hospital, Taiyuan, Shanxi, China

3Department of Oncology, Nanjing General Hospital of Nanjing Military Command, Nanjing, Jiangsu, China

4Department of Oncology, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China

Correspondence to:

Mingzhi Zhang, email: [email protected]

Keywords: extranodal natural killer/T cell lymphoma, DDGP regimen, chemotherapy, gemcitabine, pegaspargase

Received: January 29, 2016     Accepted: July 09, 2016     Published: August 9, 2016

ABSTRACT

Extranodal natural killer/T cell lymphoma (ENKL) is a high invasive disease with poor prognosis. Since there is no consensus on standard chemotherapy, we developed an original chemotherapeutic DDGP (cisplatin, dexamethasone, gemcitabine, and pegaspargase) regimen. We retrospectively analyzed 80 patients who received DDGP chemotherapy. The primary end point was progression-free survival (PFS) and secondary end points were overall survival (OS), complete response rate (CRR), and overall response rate (ORR). The one-year PFS and OS rates were 86.0% and 88.6%, and the 2-year PFS and OS rates were 81.40% and 87.1%, respectively. The ORR and CRR of DDGP chemotherapy were 91.3% and 60.0%. The major adverse events were myelosuppression, digestive tract toxicities, and coagulation disorder. No treatment-related deaths were observed. Our results suggest that the DDGP regimen is a high effective and safe treatment for ENKL.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 11135